Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Common Equity (2018 - 2019)

Historic Common Equity for DiaMedica Therapeutics (DMAC) over the last 2 years, with Q3 2019 value amounting to $9.7 million.

  • DiaMedica Therapeutics' Common Equity rose 13600.97% to $9.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $9.7 million, marking a year-over-year increase of 13600.97%. This contributed to the annual value of $17.0 million for FY2018, which is N/A changed from last year.
  • As of Q3 2019, DiaMedica Therapeutics' Common Equity stood at $9.7 million, which was up 13600.97% from $11.7 million recorded in Q2 2019.
  • Over the past 5 years, DiaMedica Therapeutics' Common Equity peaked at $17.0 million during Q4 2018, and registered a low of $4.1 million during Q3 2018.